None listed
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed advanced (FIGO III-IV) ovarian cancer, fallopian tube cancer, and primary peritoneal cancer patients 2. Serum CA125 concentration of 2x35 U/ml or higher before initiation of treatment 3. Patients with complete remission after primary chemotherapy (excluding maintenance therapy) 4. Serum CA125 concentration below normal (upper normal level (UNL) 35U/ml) 5. Patients 18 years of age or older who gave written informed consent to this trial
Exclusion criteria
Exclusion criteria: 1. If there is an additional malignant disease that is currently in progress 2. If there is a history of benign disease accompanied by elevated CA125 before menopause 3. Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of early recurrence for which secondary tumor reduction surgery is possible | — |
Secondary
| Measure | Time frame |
|---|---|
| Difference between PFS and PFS2, Prediction accuracy of R0 success rate of secondary tumor reduction surgery, Prognostic factors when performing surgery after secondary tumor reduction, Diagnostic accuracy of CA125 EPD diagnostic criteria, Diagnostic accuracy of imaging tests in the early progression of ovarian cancer | — |
Countries
Korea, Republic of
Contacts
Public ContactSok Bom Kang
National Cancer Center
Outcome results
None listed